ALSO NOTED: German Merck wants to make pharma buys; Novartis breast-cancer med prevents recurrence;

> Merck KGaA is on the prowl for pharma acquisitions, CEO Ludwig Kley told a German newspaper. Report

> Novartis' breast cancer med Femara can help prevent recurrence of the disease if it's administered after a preventive regimen of Tamoxifen--even if they start the Femara years later. Report

> In the case of a curious food-and-drug recall, Gorton's said that the pills a Pennsylvania family found last month in its fish filets were over-the-counter herbal supplements; the company subsequently took 1,000 cases of those filets off the market. Report

> Scotland's National Health Service can now use Cubicin to treat severe infections caused by the MRSA superbug. Report

> India's Dabur Pharma got regulatory approval to sell its copycat version of Pfizer's chemo drug Camptosar in Italy and Denmark; the company recently launched the generic in the U.S. Report

> Keryx Biopharmaceuticals' stock price wiped out on the rocky shores of a failed late-stage trial of its lead drug, Sulonex, for diabetes. Report

> India's Dr. Reddy's Laboratories is teaming up with 7TM on a drug discovery deal for metabolic disorders. Report

> The Translational Accelerator has opened its doors to all biotech companies in Arizona--or any life sciences company thinking about moving there. Report

> Wyeth has dumped a once-promising Curis collaboration. Report

> Japanese researchers have developed a new approach to make flu vaccines that are able to combat multiple strains of influenza, including strains of the bird flu virus, according to Japan's National Institute of Infectious Diseases. Report

And Finally... Shades of Barry Bonds or just a grown-up version of caffeine-fueled test-cramming? Academic researchers and scientists admit taking Adderall or Provigil to help them wrap up papers and studies. Report

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.